Roche’s prasinezumab shows promise on PD progression with five-year data
At the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, Roche showcased new…
Roche and Zealand’s Phase II obesity trial divides analyst opinion
Roche and Zealand Pharma’s co-developed amylin analogue, petrelintide, has met its primary endpoint in a Phase II trial,…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth](https://www.europesays.com/ch/wp-content/uploads/2026/02/84b0110bbf60eb8397db0461bc3549c4-380x220.png)
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…
Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
F. Hoffmann-La Roche Ltd Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary…
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…